Francisco Trust Under Agreemen Sells 15,000 Shares of Dyadic International (NASDAQ:DYAI) Stock

Dyadic International Inc. (NASDAQ:DYAI) major shareholder Francisco Trust Under Agreemen sold 15,000 shares of Dyadic International stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $2.01, for a total transaction of $30,150.00. Following the completion of the transaction, the insider owned 3,375,664 shares in the company, valued at $6,785,084.64. This trade represents a 0.44% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Dyadic International Stock Up 9.5%

DYAI stock opened at $1.06 on Wednesday. The company has a debt-to-equity ratio of 4.08, a current ratio of 2.42 and a quick ratio of 2.42. Dyadic International Inc. has a 52-week low of $0.65 and a 52-week high of $1.35. The company has a 50-day moving average of $0.78 and a two-hundred day moving average of $0.83. The stock has a market capitalization of $38.63 million, a price-to-earnings ratio of -4.61 and a beta of 1.15.

Dyadic International (NASDAQ:DYAI) last issued its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.01). The business had revenue of $1.11 million during the quarter, compared to the consensus estimate of $0.90 million. Dyadic International had a negative return on equity of 1,005.45% and a negative net margin of 192.40%. As a group, equities research analysts anticipate that Dyadic International Inc. will post 0.13 EPS for the current year.

Key Stories Impacting Dyadic International

Here are the key news stories impacting Dyadic International this week:

• Positive Sentiment: Dyadic said global collaborations are continuing to validate its C1 platform and expand commercial potential, including work tied to Ebola preparedness, which may improve the long-term outlook for its technology. Global Collaborations Continue to Validate Dyadic’s C1 Platform and Expands Commercial Potential
• Neutral Sentiment: Recent quarterly results were mixed: revenue came in above expectations, but EPS missed estimates, keeping attention on whether Dyadic can convert its technology into sustained profitability.
• Negative Sentiment: Major shareholder Francisco Trust Under Agreement disclosed multiple recent stock sales, which may pressure sentiment because insider selling can raise concerns about near-term confidence in the shares.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Dyadic International in a research report on Wednesday, June 24th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Dyadic International has a consensus rating of “Hold” and a consensus target price of $3.00.

Institutional Investors Weigh In On Dyadic International

Institutional investors have recently modified their holdings of the business. Bank of America Corp DE boosted its position in shares of Dyadic International by 16,146.7% in the 4th quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 26,965 shares during the last quarter. Landscape Capital Management L.L.C. bought a new stake in Dyadic International in the third quarter valued at about $190,000. Marathon Capital Management acquired a new position in Dyadic International in the third quarter valued at about $41,000. Apis Capital Advisors LLC bought a new position in Dyadic International during the third quarter worth about $1,817,000. Finally, Geode Capital Management LLC grew its position in shares of Dyadic International by 13.7% during the 4th quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock worth $284,000 after buying an additional 36,266 shares during the period. Institutional investors and hedge funds own 27.95% of the company’s stock.

Dyadic International Company Profile

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.